Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease
{{output}}
Background: Infliximab (IFX) exposure is established as a predictive factor of pharmacokinetic (PK) origin in inflammatory bowel disease (IBD), and expert consensus is to achieve adequate exposure during induction to achieve and ... ...
